According to Cognitive Market Research, the global Oncolytic Virus Therapy market size was USD 115.5 million in 2024. It will expand at a compound annual growth rate (CAGR) of 22.20% from 2024 to 2031.
North America held the major market share for more than 40% of the global revenue with a market size of USD 46.20 million in 2024 and will grow at a compound annual growth rate (CAGR) of 20.4% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 34.65 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 26.57 million in 2024 and will grow at a compound annual growth rate (CAGR) of 24.2% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 5.78 million in 2024 and will grow at a compound annual growth rate (CAGR) of 21.6% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 2.31 million in 2024 and will grow at a compound annual growth rate (CAGR) of 21.9% from 2024 to 2031.
The oncolytic viral therapies and cancer vaccines category is the fastest growing segment of the Oncolytic Virus Therapy industry
